Skip to main content

WE BUILD EXTRAORDINARY VENTURES

We breed startups that create value,
ultimately contributing to the common good.

Learn More

At adVentures, we breed innovative startups that create value, ultimately contributing to the common good.

We create ventures that enable efficiency and collaboration on a global scale. By combining technologies and entrepreneurial talents, we strive to overcome unanswered challenges.

We pioneer by taking calculated risks, leveraging technology whether that be digital, AI or genetics. And when appropriate, our scientists and engineers go beyond the frontiers. Our model favours frugal innovation and synergies across the portfolio.

We believe small teams make the boldest changes. We’ve built our studio as a learning organization, nurturing individuals, growing together as entrepreneurs.

Entrepreneurship is a craft, not a gamble.

Antoine Duboscq Picture

Antoine Duboscq
CEO adVentures Startup Studio

Teamwork solution

Genetic engineering deeptech

Know-how marketplace

Art Collections sharing platform

Biosphere Venture Studio

Education Training Centre

Global Market Niches

Our strategic mindset stresses the value of agility and creativity and is at the heart of all our initiatives. We spot early, or even create new global market niches that leverage technology.

A Unique Talent Pool

adVentures attracts talents from diverse business and scientific horizons, with a common mindset : global perspective, agility, hard work, high ethical standards, teamwork, willingness to make impactful contributions.

Building sustainable value

We manage our portfolio to create sustainable value, and mitigate the risks. Each venture is grown along specific value creation drivers and indicators. And each venture is expected to contribute to the common good.

Latest News

NewsGEG TechGEG-Tech Releases new mRNA nanoparticles for prime & base editing
October 9, 2024

GEG-Tech Releases new mRNA nanoparticles for prime & base editing

First scientific agreement between a French deep-tech company and the Broad Institute of MIT & Harvard, the prestigious institute, a world leader in genetic engineering and inventor of the CRISPR…
NewsWimiWimi and French Agency CSTB create Joint-Venture
October 7, 2024

Wimi and French Agency CSTB create Joint-Venture

By creating the joint venture KROQI SAS, the CSTB (Scientific and Technical Center for Building) and WIMI (sovereign and secure collaborative suite) are partnering to accelerate the development of KROQI,…
adVenturesNewsAntoine Duboscq’s Portrait in “Les Echos”
June 13, 2024

Antoine Duboscq’s Portrait in “Les Echos”

adVentures' founder, Antoine DUBOSCQ has had his portrait written by Julie LE BOLZER in French Economic and Business Newspaper "Les Echos".
NewsGEG TechGEG-Tech Lab moves to the heart of the Saclay Plateau
June 3, 2024

GEG-Tech Lab moves to the heart of the Saclay Plateau

GEG-Tech joined the Spartners bio-park in June 2024, which brings together cutting-edge biotech companies in the field of biotechnology in the heart of the Saclay Plateau near the École Normale…
NewsWimiWimi Leadership Team publishes in CRSI
May 27, 2024

Wimi Leadership Team publishes in CRSI

Discover the article "Cybercrime: The End of Digital Carelessness" in the CRSI - Centre de Réflexion sur la Sécurité Intérieure's internal security newsletter, co-authored by the President of Wimi, Antoine…
Alte AcademiaNewsLaunch of Alte Academia
May 21, 2024

Launch of Alte Academia

Launch of Alte Academia, the first training center in France dedicated to Integral Education, with over twenty high-level trainers and experts already on board to train education professionals and business…
NewsWimiWimi on BFM Business
April 2, 2024

Wimi on BFM Business

Early April 2024, on BFM Business, the President of Wimi, Antoine DUBOSCQ, appeared on the show "Good Morning Business" to discuss the challenges of #cybersecurity and #digitalsovereignty, as well as…
NewsGEG TechGEG-Tech publishes new patents
March 27, 2024

GEG-Tech publishes new patents

GEG Tech has recently published a set of patents broading its existing IP about its biological mRNA nanoparticle, in the field of vaccination, genome editing for gene therapy and dermatology.
adVentures

Can we do something together?